Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?

Glucagon-like peptide-1 (GLP-1) agonists have taken the healthcare world by storm, emerging as mainstream treatments for patients with diabetes or obesity. Some of these medications include Novo Nordisk's (NYSE: NVO) Ozempic, Wegovy, Rybelsus, and Saxenda, and Eli Lilly's (NYSE: LLY) Mounjaro and Zepbound.Below, I'll dig into which pharmaceutical stock I think is the better buy for the long run. While Novo Nordisk and Lilly each carry encouraging prospects, I see one of these companies as the superior opportunity.Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of notable wins have me thinking this lead will widen.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool